LAMEA Stroke Management Market By Type (Diagnostics - Computed Tomography Scan, Magnetic Resonance Imaging, Echocardiography, Carotid Ultrasound, Cerebral Angiography, Electrocardiography; Therapeutics - Tissue Plasminogen Activator, Anticoagulant, Antiplatelet), Application (Ischemic, Haemorrhagic)
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the LAMEA Stroke Management Market
Market Report Description
The Latin America, Middle East and Africa Stroke Management Market would witness market growth of 8.0% CAGR during the forecast period (2018 – 2024). Stroke is a medical emergency which occurs when the flow of the blood is restricted to the brain and as a result, brain cells start dying. Rise in incidence and prevalence of chronic diseases has been a major factor that is responsible for the growth of the stroke management market. Additionally, growing geriatric population, which is highly susceptible to strokes, growing diabetic population and usage of tobacco are other factors that are driving the growth of the market. However, the cost associated with the treatment and stringent government regulations pertaining to the approval of new and advances devices and drugs would limit the market growth. Rising investments to upgrade healthcare systems and demand for technologically advanced devices for rapid & accurate distribution of medicines are the factors that are driving the market in the region. Research and development activities in the region would further add to the market attractiveness in the region.
Based on Application, the market is segmented into Ischemic Stroke and Hemorrhagic Stroke. Based on Type, the market is segmented into Diagnostics and Therapeutics. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, B. Braun Melsungen Ag, Boston Scientific Corporation, Cardinal Health, Inc., Ge Healthcare, Glaxosmithkline Plc, Medtronic Plc., Siemens Aktiengesellschaft, Merck & Co., Inc., and Bristol-Myers Squibb Company.
Scope of the Study
- Computed Tomography Scan (CT Scan)
- Magnetic Resonance Imaging (MRI)
- Carotid Ultrasound
- Cerebral Angiography
- Tissue Plasminogen Activator
- Other Therapeutics Type
- Ischemic Stroke
- Hemorrhagic Stroke
- Saudi Arabia
- South Africa
- Rest of LAMEA
- ABBOTT Laboratories
- B. Braun Melsungen Ag
- Boston Scientific Corporation
- Cardinal Health, Inc.
- Ge Healthcare
- Glaxosmithkline Plc
- Medtronic Plc
- Siemens Aktiengesellschaft
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free